Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
4914 | 1634 | 25.5 | 70% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
116 | 23742 | STAPHYLOCOCCUS AUREUS//MRSA//METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | VANCOMYCIN | Author keyword | 105 | 21% | 28% | 453 |
2 | TEICOPLANIN | Author keyword | 59 | 32% | 9% | 155 |
3 | FUNCEI | Address | 12 | 86% | 0% | 6 |
4 | RED MAN SYNDROME | Author keyword | 7 | 57% | 0% | 8 |
5 | VANCOMYCIN VCM | Author keyword | 6 | 100% | 0% | 4 |
6 | VANCOMYCIN DOSAGE | Author keyword | 4 | 75% | 0% | 3 |
7 | DOSING NOMOGRAM | Author keyword | 3 | 60% | 0% | 3 |
8 | TROUGH CONCENTRATION | Author keyword | 3 | 26% | 1% | 9 |
9 | MANAGEMENT OF CLINICAL USE OF VANCOMYCIN | Author keyword | 2 | 67% | 0% | 2 |
10 | NON INPATIENT THERAPY | Author keyword | 2 | 67% | 0% | 2 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | VANCOMYCIN | 105 | 21% | 28% | 453 | Search VANCOMYCIN | Search VANCOMYCIN |
2 | TEICOPLANIN | 59 | 32% | 9% | 155 | Search TEICOPLANIN | Search TEICOPLANIN |
3 | RED MAN SYNDROME | 7 | 57% | 0% | 8 | Search RED+MAN+SYNDROME | Search RED+MAN+SYNDROME |
4 | VANCOMYCIN VCM | 6 | 100% | 0% | 4 | Search VANCOMYCIN+VCM | Search VANCOMYCIN+VCM |
5 | VANCOMYCIN DOSAGE | 4 | 75% | 0% | 3 | Search VANCOMYCIN+DOSAGE | Search VANCOMYCIN+DOSAGE |
6 | DOSING NOMOGRAM | 3 | 60% | 0% | 3 | Search DOSING+NOMOGRAM | Search DOSING+NOMOGRAM |
7 | TROUGH CONCENTRATION | 3 | 26% | 1% | 9 | Search TROUGH+CONCENTRATION | Search TROUGH+CONCENTRATION |
8 | MANAGEMENT OF CLINICAL USE OF VANCOMYCIN | 2 | 67% | 0% | 2 | Search MANAGEMENT+OF+CLINICAL+USE+OF+VANCOMYCIN | Search MANAGEMENT+OF+CLINICAL+USE+OF+VANCOMYCIN |
9 | NON INPATIENT THERAPY | 2 | 67% | 0% | 2 | Search NON+INPATIENT+THERAPY | Search NON+INPATIENT+THERAPY |
10 | PHARMACOKINETIC DATA MINING | 2 | 67% | 0% | 2 | Search PHARMACOKINETIC+DATA+MINING | Search PHARMACOKINETIC+DATA+MINING |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | RED MAN SYNDROME | 44 | 61% | 3% | 46 |
2 | TEICHOMYCIN | 33 | 83% | 1% | 19 |
3 | STUDY COMPARING VANCOMYCIN | 26 | 80% | 1% | 16 |
4 | TROUGH CONCENTRATIONS | 17 | 43% | 2% | 31 |
5 | INTERMITTENT INFUSION | 14 | 32% | 2% | 37 |
6 | FLUORESCENCE POLARIZATION IMMUNOASSAY | 14 | 19% | 4% | 65 |
7 | ADMINISTRATION REGIMENS | 14 | 100% | 0% | 7 |
8 | ONE COMPARTMENT | 10 | 73% | 0% | 8 |
9 | TEICOPLANIN | 10 | 11% | 5% | 83 |
10 | HIGH DOSE VANCOMYCIN | 9 | 64% | 1% | 9 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
---|---|---|---|---|
Systematic Review and Meta-Analysis of Vancomycin-Induced Nephrotoxicity Associated with Dosing Schedules That Maintain Troughs between 15 and 20 Milligrams per Liter | 2013 | 50 | 56 | 68% |
Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy | 2011 | 57 | 13 | 85% |
Vancomycin A Review of Population Pharmacokinetic Analyses | 2012 | 35 | 36 | 81% |
Vancomycin Loading Doses: A Systematic Review | 2015 | 1 | 20 | 60% |
Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review | 2012 | 35 | 63 | 76% |
Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis | 2015 | 1 | 41 | 54% |
Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis | 2012 | 50 | 29 | 45% |
The comparative efficacy and safety of teicoplanin and vancomycin | 1996 | 126 | 22 | 82% |
Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections | 2004 | 260 | 55 | 24% |
Recent changes in vancomycin use in renal failure | 2010 | 29 | 21 | 76% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | FUNCEI | 12 | 86% | 0.4% | 6 |
2 | ANTIMICROBIAL REFERENCE | 1 | 50% | 0.1% | 2 |
3 | SERV CONTROL EPIDEMIOL | 1 | 100% | 0.1% | 2 |
4 | NEPHROL INFECT DIS | 1 | 19% | 0.2% | 4 |
5 | CLIN INVEST CIC9202 | 1 | 23% | 0.2% | 3 |
6 | ANESTHESIA INTENS CARE MED 2 | 1 | 50% | 0.1% | 1 |
7 | BAYCARE HLTH SYST | 1 | 50% | 0.1% | 1 |
8 | CARDIOTHORAC VASC ANESTHESIA CRIT CARE M | 1 | 50% | 0.1% | 1 |
9 | CENT ICU | 1 | 50% | 0.1% | 1 |
10 | CERTIFICAT EVALUAT | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000173593 | DAPTOMYCIN//TELAVANCIN//HVISA |
2 | 0.0000117124 | BURNS TRAUMA CRIT CARE//MUTANT SELECTION WINDOW//ANTIINFECT DEV |
3 | 0.0000088049 | AMINOGLYCOSIDES//AMIKACIN//TOBRAMYCIN |
4 | 0.0000086660 | BALHIMYCIN//GLYCOPEPTIDE ANTIBIOTICS//COMPLESTATIN |
5 | 0.0000067123 | TETRACYCLINE RESISTANCE PLASMID//BACTERIOPHAGE TYPING//PI9789 |
6 | 0.0000062049 | SECTOR MICROBIOL//STAPHYLOCOCCUS AUREUS BACTEREMIA//STAPHYLOCOCCUS AUREUS BACTERAEMIA |
7 | 0.0000060685 | BUNDESSTAATL BAKTERIOL SEROL UNTERSUCHUNGSANSTALT//KINDERHEILKUNDE KLIN PEDIATINFEKT ABT//ANTIMICROBIAL INTERACTION |
8 | 0.0000060325 | LINEZOLID//OXAZOLIDINONE//LINEZOLID RESISTANCE |
9 | 0.0000051933 | DALFOPRISTIN//QUINUPRISTIN//QUINUPRISTIN DALFOPRISTIN |
10 | 0.0000050867 | DOSE BANDING//CHEMOTHERAPY DOSING//GRANULOCYTE MACROPHAGE PROGENITOR CELLS CFU GM |